Return to Listing

8 result(s) for Urologic / Genitourinary Cancers

PI Name Protocol # Title
Christopher Ryan IRB00007404 S0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Christopher Ryan IRB00009241 Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Matthew Taylor IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Jeremy Cetnar STUDY00015245 S1314: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Jeremy Cetnar STUDY00015597 A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versusPlacebo in Subjects with High Risk Invasive Urothelial Carcinoma
Jeremy Cetnar STUDY00015834 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors
Christopher Ryan STUDY00016085 A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Jeremy Cetnar STUDY00016393 A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080